Jonathan W Friedberg, MD, MMSc, University of Rochester, Rochester, NY, shares some insights into how the treatment landscape of diffuse large Bcell lymphoma (DLBCL) is changing, drawing focus on the promise of polaRCHP. Dr Friedberg first highlights the heterogeneity of DLBCL, and then goes on to discuss the promise of polaRCHP compared to RCHOP, based on findings from the POLARIX study (NCT03274492). This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.